These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34795208)

  • 1. Safety and efficacy of thalidomide in patients with transfusion-dependent β-thalassemia: a randomized clinical trial.
    Chen JM; Zhu WJ; Liu J; Wang GZ; Chen XQ; Tan Y; Xu WW; Qu LW; Li JY; Yang HJ; Huang L; Cai N; Wang WD; Huang K; Xu JQ; Li GH; He S; Luo TY; Huang Y; Liu SH; Wu WQ; Lu QY; Zhou MG; Chen SY; Li RL; Hu ML; Huang Y; Wei JH; Li JM; Chen SJ; Zhou GB
    Signal Transduct Target Ther; 2021 Nov; 6(1):405. PubMed ID: 34795208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia.
    Cappellini MD; Viprakasit V; Taher AT; Georgiev P; Kuo KHM; Coates T; Voskaridou E; Liew HK; Pazgal-Kobrowski I; Forni GL; Perrotta S; Khelif A; Lal A; Kattamis A; Vlachaki E; Origa R; Aydinok Y; Bejaoui M; Ho PJ; Chew LP; Bee PC; Lim SM; Lu MY; Tantiworawit A; Ganeva P; Gercheva L; Shah F; Neufeld EJ; Thompson A; Laadem A; Shetty JK; Zou J; Zhang J; Miteva D; Zinger T; Linde PG; Sherman ML; Hermine O; Porter J; Piga A;
    N Engl J Med; 2020 Mar; 382(13):1219-1231. PubMed ID: 32212518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association of HBG2, BCL11A, and HBS1L-MYB polymorphisms to thalidomide response in Chinese β-thalassemia patients.
    Yang K; Wu Y; Ma Y; Xiao J; Zhou Y; Yin X
    Blood Cells Mol Dis; 2020 Sep; 84():102442. PubMed ID: 32387854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term clinical efficacy and safety of thalidomide in patients with transfusion-dependent β-thalassemia: results from Thal-Thalido study.
    Ali Z; Ismail M; Rehman IU; Rani GF; Ali M; Khan MTM
    Sci Rep; 2023 Aug; 13(1):13592. PubMed ID: 37604857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy of thalidomide for various genotypes of beta thalassemia.
    Yang WJ; Kang QP; Zhou Q; Lin T; Gong XM; Huang CJ; Dou M; Lin Y
    BMC Med Genomics; 2024 Jul; 17(1):191. PubMed ID: 39026312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of efficacy and safety of thalidomide vs hydroxyurea in patients with Hb E-β thalassemia - a pilot study from a tertiary care Centre of India.
    Jain M; Chakrabarti P; Dolai TK; Ghosh P; Mandal PK; Baul SN; De R
    Blood Cells Mol Dis; 2021 May; 88():102544. PubMed ID: 33610115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents.
    Santini V; Almeida A; Giagounidis A; Gröpper S; Jonasova A; Vey N; Mufti GJ; Buckstein R; Mittelman M; Platzbecker U; Shpilberg O; Ram R; Del Cañizo C; Gattermann N; Ozawa K; Risueño A; MacBeth KJ; Zhong J; Séguy F; Hoenekopp A; Beach CL; Fenaux P
    J Clin Oncol; 2016 Sep; 34(25):2988-96. PubMed ID: 27354480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience with combination of hydroxyurea and low-dose thalidomide in transfusion-dependent beta thalassemia patients.
    Bhurani D; Kapoor J; Yadav N; Khushoo V; Agrawal N; Ahmed R; Arora JS; Mehta P
    Ann Hematol; 2021 Jun; 100(6):1417-1427. PubMed ID: 33811502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thalidomide and Hydroxyurea in Transfusion-Dependent Thalassemia: Efficacy, Safety Profile and Impact on Quality of Life.
    Bhattacharjee S; Ghosh S; Shaw J; Bhattacharjee S; Bhattacharyya M
    Hemoglobin; 2024 May; 48(3):161-168. PubMed ID: 39092801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Thalidomide in Patients With Transfusion-Dependent Thalassemia.
    Chandra J; Parakh N; Sidharth ; Singh N; Sharma S; Goel M; Pemde H
    Indian Pediatr; 2021 Jul; 58(7):611-616. PubMed ID: 34315832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thalidomide for Patients with β-Thalassemia: A Multicenter Experience.
    Yang K; Wu Y; Zhou Y; Long B; Lu Q; Zhou T; Wang L; Geng Z; Yin X
    Mediterr J Hematol Infect Dis; 2020; 12(1):e2020021. PubMed ID: 32395210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia.
    Piga A; Perrotta S; Gamberini MR; Voskaridou E; Melpignano A; Filosa A; Caruso V; Pietrangelo A; Longo F; Tartaglione I; Borgna-Pignatti C; Zhang X; Laadem A; Sherman ML; Attie KM
    Blood; 2019 Mar; 133(12):1279-1289. PubMed ID: 30617198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Predictors of Hematologic Responses in Patients with Non-Transfusion-Dependent β-Thalassemia Receiving Thalidomide Therapy].
    Yang K; Yin XL; Liu XD; Hua F; Peng W; Li L; Chen K; Zhang J; Luo S; Xiao J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1519-1526. PubMed ID: 36208259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety and erythroid response with luspatercept treatment in patients with β-thalassemia.
    Piga A; Longo F; Gamberini MR; Voskaridou E; Ricchi P; Caruso V; Pietrangelo A; Zhang X; Shetty JK; Attie KM; Tartaglione I
    Ther Adv Hematol; 2022; 13():20406207221134404. PubMed ID: 36505885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase 2 Randomized Controlled Trial of Single-Agent Hydroxyurea Versus Thalidomide Among Adult Transfusion Dependent β Thalassemia Patients.
    Bhattacharjee U; Khadwal A; Shafiq N; Lad D; Sharma P; Das R; Shukla P; Jain A; Prakash G; Malhotra P
    Indian J Hematol Blood Transfus; 2023 Apr; 39(2):266-275. PubMed ID: 36620489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of efficacy of packed red blood cell transfusion based on its hemoglobin content versus the standard transfusion practice in thalassemia major patients (HEMOCON study).
    Raja A; Jain A; Marwaha N; Trehan A
    Transfus Apher Sci; 2020 Jun; 59(3):102736. PubMed ID: 32019736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Effect of Blood Transfusion on Growth of Patients with Hb E/β-Thalassemia.
    Chuansumrit A; Sirachainan N; Kitpoka P; Kadegasem P; Songdej D; Sasanakul W; Wongwerawattanakoon P
    Hemoglobin; 2019; 43(4-5):264-272. PubMed ID: 31760834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Thalidomide Treatment in Children With Transfusion Dependent β-Thalassemia: A Retrospective Clinical Study.
    Li X; Hu S; Liu Y; Huang J; Hong W; Xu L; Xu H; Fang J
    Front Pharmacol; 2021; 12():722502. PubMed ID: 34456732
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-Term Follow-Up of Patients Undergoing Thalidomide Therapy for Transfusion-Dependent β-Thalassaemia: A Single-Center Experience.
    Zhu W; He Y; Huang M; Fu S; Liu Z; Wang X; Li Z; Li X; Chen J; Li Y
    Int J Gen Med; 2024; 17():1729-1738. PubMed ID: 38711824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigating the Efficacy and Safety of Thalidomide for Treating Patients With
    Lu Y; Wei Z; Yang G; Lai Y; Liu R
    Front Pharmacol; 2021; 12():814302. PubMed ID: 35087410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.